日本EGFR T790M阳性NSCLC患者奥希替尼治疗期间间质性肺病发生因素与影像学特征的真实世界评估
基于日本上市后真实世界数据,分析3578例EGFR T790M阳性NSCLC患者接受二线或后线奥希替尼治疗时间质性肺病(ILD)的发生情况。医生报告245例(6.8%)发生ILD,专家委员会评估231例(6.5%)为ILD,中位首次发生时间为63.0天。既往纳武利尤单抗治疗史和ILD病史或合并ILD是与奥希替尼治疗期间ILD发生的潜在相关因素。
要点
- 奥希替尼治疗期间ILD发生率为6.8%(医生报告)或6.5%(专家评估)。
- 既往纳武利尤单抗治疗史与ILD风险升高相关(调整OR 2.84)。
- ILD病史或合并ILD与ILD风险升高相关(调整OR 3.51)。
核心结论
- 日本人群中奥希替尼相关ILD的频率与已知安全性特征一致。
- ILD病史或合并ILD以及既往纳武利尤单抗治疗史是与奥希替尼治疗期间ILD发生的潜在相关因素。
研究设计与样本
- 基于日本上市后真实世界数据的回顾性分析,纳入3578例接受二线或后线奥希替尼治疗的EGFR突变阳性NSCLC患者。
- 由医生报告ILD不良药物反应,并由日本ILD专家委员会评估ILD发生情况,同时对发生ILD的患者进行回顾性影像学评估。
主要发现
- 3578例患者中,医生报告245例(6.8%)发生252起ILD事件,专家委员会评估231例(6.5%)为ILD。
- 奥希替尼治疗开始后首次ILD发生的中位时间(范围)为63.0(5-410)天,报告29例致命性结局。
- 既往纳武利尤单抗治疗史与ILD发生的调整OR为2.84(95%CI 1.98-4.07)。
- ILD病史或合并ILD与ILD发生的调整OR为3.51(95%CI 2.10-5.87)。
- 既往接受纳武利尤单抗治疗的患者中,在开始奥希替尼前1个月内停用纳武利尤单抗者ILD发生数量和比例最高,随着纳武利尤单抗停药至奥希替尼开始的时间延长,发生率和比例呈下降趋势。
临床怎么用
- 对具有ILD病史或合并ILD以及既往纳武利尤单抗治疗史的患者,在奥希替尼治疗期间应加强ILD监测。
- 对于近期停用纳武利尤单抗的患者,启动奥希替尼时需警惕ILD风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Using real-world Japanese postmarketing data, we characterized interstitial lung disease (ILD) development during the second- or later-line osimertinib treatment for EGFR mutation-positive NSCLC. Retrospective radiologic image evaluation of patients developing ILD was also performed. METHODS: Patients who had ILD events reported as an adverse drug reaction by their physicians and who were assessed as having developed ILD as assessed by an ILD expert committee in Japan were included. RESULTS: Among 3578 patients, 252 ILD events were reported in 245 patients (6.8%) by their attending physicians. The median (range) time to the first onset of ILD after osimertinib treatment initiation was 63.0 (5-410) days, and 29 patients with a fatal outcome were reported. The ILD expert committee assessed 231 of 3578 patients (6.5%) as having ILD. A previous history of nivolumab therapy (adjusted OR: 2.84; 95% confidence interval: 1.98-4.07) and a history or concurrence of ILD (3.51; 2.10-5.87) were identified as factors potentially associated with ILD onset during osimertinib treatment. In patients who had received a previous nivolumab treatment, the number and proportion of patients developing ILD were highest for patients who discontinued nivolumab treatment within the first month before initiating osimertinib; trends for decreasing incidence and proportion were observed, with an increasing duration between the end of nivolumab treatment and the initiation of osimertinib treatment. CONCLUSIONS: The frequency of ILD was consistent with the known osimertinib safety profile in the Japanese population. A history or concurrence of ILD and history of previous nivolumab therapy are factors potentially associated with ILD onset during osimertinib treatment.
引用
- Gemma A, Kusumoto M, Sakai F, et al. Real-World Evaluation of Factors for Interstitial Lung Disease Incidence and Radiologic Characteristics in Patients With EGFR T790M-positive NSCLC Treated With Osimertinib in Japan. J Thorac Oncol. 2020. PMID: 32927121. doi:10.1016/j.jtho.2020.08.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。